Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 28, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 28, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $472.43 ($132,280) on September 28, 2026; holds 333,663 after (Indirect).
- Open-market sale: disposed of 600 Common Stock at $473.28 ($283,966) on September 28, 2026; holds 333,063 after (Indirect).
- Open-market sale: disposed of 680 Common Stock at $474.46 ($322,629) on September 28, 2026; holds 332,383 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $475.28 ($38,022) on September 28, 2026; holds 332,303 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $476.68 ($76,268) on September 28, 2026; holds 332,143 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $477.45 ($95,490) on September 28, 2026; holds 331,943 after (Indirect).
- Open-market sale: disposed of 601 Common Stock at $479.06 ($287,913) on September 28, 2026; holds 331,342 after (Indirect).
- Open-market sale: disposed of 1,013 Common Stock at $480.18 ($486,427) on September 28, 2026; holds 330,329 after (Indirect).
- Open-market sale: disposed of 1,354 Common Stock at $481.20 ($651,542) on September 28, 2026; holds 328,975 after (Indirect).
- Open-market sale: disposed of 693 Common Stock at $482.11 ($334,104) on September 28, 2026; holds 328,282 after (Indirect).
- Open-market sale: disposed of 1,539 Common Stock at $483.20 ($743,648) on September 28, 2026; holds 326,743 after (Indirect).
- Open-market sale: disposed of 825 Common Stock at $484.47 ($399,685) on September 28, 2026; holds 325,918 after (Indirect).
- Open-market sale: disposed of 1,315 Common Stock at $485.45 ($638,373) on September 28, 2026; holds 324,603 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $486.00 ($77,761) on September 28, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 28, 2026; holds 347,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,568,106 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-28 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-28 | Open-market sale | Common Stock | 280 | $472 | $132.3K | 333,663 |
| 2026-09-28 | Open-market sale | Common Stock | 600 | $473 | $284.0K | 333,063 |
| 2026-09-28 | Open-market sale | Common Stock | 680 | $474 | $322.6K | 332,383 |
| 2026-09-28 | Open-market sale | Common Stock | 80 | $475 | $38.0K | 332,303 |
| 2026-09-28 | Open-market sale | Common Stock | 160 | $477 | $76.3K | 332,143 |
| 2026-09-28 | Open-market sale | Common Stock | 200 | $477 | $95.5K | 331,943 |
| 2026-09-28 | Open-market sale | Common Stock | 601 | $479 | $287.9K | 331,342 |
| 2026-09-28 | Open-market sale | Common Stock | 1,013 | $480 | $486.4K | 330,329 |
| 2026-09-28 | Open-market sale | Common Stock | 1,354 | $481 | $651.5K | 328,975 |
| 2026-09-28 | Open-market sale | Common Stock | 693 | $482 | $334.1K | 328,282 |
| 2026-09-28 | Open-market sale | Common Stock | 1,539 | $483 | $743.6K | 326,743 |
| 2026-09-28 | Open-market sale | Common Stock | 825 | $484 | $399.7K | 325,918 |
| 2026-09-28 | Open-market sale | Common Stock | 1,315 | $485 | $638.4K | 324,603 |
| 2026-09-28 | Open-market sale | Common Stock | 160 | $486 | $77.8K | 324,443 |
| 2026-09-28 | Option exercise/conversion | Stock Option | 9,500 | — | — | 347,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-28 | Option exercise/conversion (9,500 shares) |
| 2026-09-28 | Open-market sale (280 shares) |
| 2026-09-28 | Open-market sale (600 shares) |
| 2026-09-28 | Open-market sale (680 shares) |
| 2026-09-28 | Open-market sale (80 shares) |
| 2026-09-28 | Open-market sale (160 shares) |
| 2026-09-28 | Open-market sale (200 shares) |
| 2026-09-28 | Open-market sale (601 shares) |
| 2026-09-28 | Open-market sale (1,013 shares) |
| 2026-09-28 | Open-market sale (1,354 shares) |
| 2026-09-28 | Open-market sale (693 shares) |
| 2026-09-28 | Open-market sale (1,539 shares) |
| 2026-09-28 | Open-market sale (825 shares) |
| 2026-09-28 | Open-market sale (1,315 shares) |
| 2026-09-28 | Open-market sale (160 shares) |
| 2026-09-28 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.